Devyser Diagnostics AB (Nasdaq: DVYSR) (STO:DVYSR), a provider of genetic test kits for laboratories, on Tuesday declared financial information for its full year from January to December 2022.
The company reported a loss after tax of SEK46.0m, compared to a loss of SEK20.7m in the previous year.
Earnings per share before and after dilution amounted to a loss of SEK2.89 in 2022, versus a loss of SEK1.85 in the year before.
Net sales increased by 35.4% to SEK126.6m, over SEK93.5 in 2021.
Devyser added that its board proposes no dividend for 2022.
Egetis secures exclusive licence agreement with Fujimoto for Emcitate development in Japan
Perrigo announces quarterly dividend
Eli Lilly announces Q4 2023 dividend
Moderna and CEPI partner to accelerate mRNA vaccine development
OptiBiotix secures license agreement with Tata Chemicals for Indian market